Author： Furlong Clement E Cole Toby B Jarvik Gail P Costa Lucio G
Publisher： Future Medicine
ISSN： 1462-2416
Source： Pharmacogenomics, Vol.3, Iss.3, 2002-05, pp. : 341-348
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Related content
Angiotensin II receptor polymorphisms in hypertension. Pharmacogenomic considerations
By Baudin Bruno
Pharmacogenomics, Vol. 3, Iss. 1, 2002-01 ,pp. :
Access to resources
Recommend
Pharmacogenomic considerations for immunosuppressive therapy
Pharmacogenomics, Vol. 4, Iss. 3, 2003-05 ,pp. :
Pharmacogenomic considerations in drug delivery
By Attar Mayssa Lee Vincent HL
Pharmacogenomics, Vol. 4, Iss. 4, 2003-07 ,pp. :
Tolcapone, COMT polymorphisms and pharmacogenomic treatment of schizophrenia
By Bitsios Panos Roussos Panos
Pharmacogenomics, Vol. 12, Iss. 4, 2011-04 ,pp. :